Showing results (301-310 of 410) with videos related to
Sort By:
Pageof 41
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.JAMA Oncology|February 26, 2016
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and VulvaBrooke E Howitt, Heather H Sun, Margaretha G M Roemer, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2013
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaDennie T Frederick, Adriano Piris, Alexandria P Cogdill, et al.Blood Advances|November 22, 2021
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trialVincent T Ho, Haesook T Kim, Jennifer Brock, et al.The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell CarcinomaMiriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.Pageof 41